■近年来,前列腺癌(PC)基因检测的适应症已从有前列腺癌和/或相关癌症家族史的患者扩展到患有晚期去势抵抗疾病的患者,甚至对早期PC患者进行主动监测是否合适。目前的共识旨在为泌尿科医师提供指导,肿瘤学家和病理学家与亚洲PC患者合作,研究在选定人群中测试谁和什么。
■香港泌尿外科协会和香港肿瘤学会的联合共识小组在一系列5个物理和虚拟会议上召开。在PubMed中进行了关于PC基因检测的背景文献检索,ClinicalKey,EBSCOHost,Ovid和ProQuest,并成立了三个工作分组审查和提出相关证据。会议议程采用了修改后的德尔菲方法,以确保讨论以结构化的方式进行,迭代和平衡的方式,随后对候选人声明进行了匿名投票。在5个可用的答案选项中,如果≥75%的小组成员选择“完全接受”(选项A)或“保留接受”(选项B),则接受共识声明。
■共识分为三个部分:测试适应症,测试方法,和治疗意义。列出了35份候选陈述,其中31人被接受。这些声明解决了将PC基因检测数据和指南应用于亚洲患者的问题,包括进行种系测试的患者选择,基因组和组织样本的选择,提供遗传咨询,以及在转移性去势耐药的PC患者中使用新型全身治疗方法。
■这一共识为泌尿科医师提供了指导,肿瘤学家和病理学家与亚洲患者一起研究基因检测的适应症,测试方法和技术考虑,以及相关的治疗意义。
UNASSIGNED: In recent years, indications for genetic testing in prostate cancer (PC) have expanded from patients with a family history of prostate and/or related cancers to those with advanced castration-resistant disease, and even to early PC patients for determination of the appropriateness of active surveillance. The current
consensus aims to provide guidance to urologists, oncologists and pathologists working with Asian PC patients on who and what to test for in selected populations.
UNASSIGNED: A joint
consensus panel from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology was convened over a series of 5 physical and virtual meetings. A background literature search on genetic testing in PC was performed in PubMed, ClinicalKey, EBSCOHost, Ovid and ProQuest, and three working subgroups were formed to review and present the relevant evidence. Meeting agendas adopted a modified Delphi approach to ensure that discussions proceed in a structured, iterative and balanced manner, which was followed by an anonymous voting on candidate statements. Of 5 available answer options, a
consensus statement was accepted if ≥ 75% of the panelists chose \"Accept Completely\" (Option A) or \"Accept with Some Reservation\" (Option B).
UNASSIGNED: The
consensus was structured into three parts: indications for testing, testing methods, and therapeutic implications. A list of 35 candidate statements were developed, of which 31 were accepted. The statements addressed questions on the application of PC genetic testing data and
guidelines to Asian patients, including patient selection for germline testing, selection of gene panel and tissue sample, provision of genetic counseling, and use of novel systemic treatments in metastatic castration-resistant PC patients.
UNASSIGNED: This consensus provides guidance to urologists, oncologists and pathologists working with Asian patients on indications for genetic testing, testing methods and technical considerations, and associated therapeutic implications.